Hormone 'Whiplash' therapy shows promise for tough prostate cancer

NCT ID NCT04558866

First seen Feb 17, 2026 · Last updated May 13, 2026 · Updated 8 times

Summary

This study tests a new approach called extreme bipolar androgen therapy (ExBAT) for men with a hard-to-treat type of advanced prostate cancer. It combines a standard drug (darolutamide) with high doses of testosterone to try to control the cancer. The study includes 51 men and aims to see if this combination can slow down the disease.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PROSTATE CANCER are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Locations

  • CTTB - Centro de Tratamento de Tumores Botafogo (Oncoclínicas)

    Rio de Janeiro, Rio de Janeiro, 22.250-905, Brazil

  • HIAE - Hospital Israelita Albert Einstein

    São Paulo, São Paulo, 05.653-000, Brazil

  • HMV - Hospital Moinhos de Vento

    Porto Alegre, Rio Grande do Sul, 90.035-000, Brazil

  • Hospital São Rafael - Oncologia D'Or BA

    Salvador, Estado de Bahia, 41.253-190, Brazil

  • Hospital Sírio-Libanês DF

    Brasília, Federal District, 70.200-730, Brazil

  • Hospital Sírio-Libanês SP

    São Paulo, São Paulo, 01.308-050, Brazil

Conditions

Explore the condition pages connected to this study.